Haemonetics Corporation (NYSE:HAE) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, November 7th. Analysts expect Haemonetics Corporation to post earnings of $0.42 per share for the quarter.

Haemonetics Corporation (NYSE:HAE) last released its earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.02. Haemonetics Corporation had a net margin of 0.48% and a return on equity of 11.07%. The firm had revenue of $211.00 million for the quarter, compared to analyst estimates of $211.29 million. During the same period in the prior year, the firm earned $0.25 earnings per share. The business’s quarterly revenue was up .5% compared to the same quarter last year. On average, analysts expect Haemonetics Corporation to post $1.61 EPS for the current fiscal year and $1.8 EPS for the next fiscal year.

Haemonetics Corporation (NYSE:HAE) traded up 0.72% during mid-day trading on Tuesday, hitting $47.45. 30,691 shares of the company were exchanged. Haemonetics Corporation has a 12 month low of $33.01 and a 12 month high of $47.88. The stock has a market cap of $2.50 billion, a price-to-earnings ratio of 616.23 and a beta of 0.87. The firm has a 50 day moving average price of $44.75 and a 200 day moving average price of $42.08.

TRADEMARK VIOLATION NOTICE: “Haemonetics Corporation (HAE) Set to Announce Earnings on Tuesday” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/31/haemonetics-corporation-hae-set-to-announce-earnings-on-tuesday.html.

Several equities research analysts recently commented on the company. TheStreet upgraded Haemonetics Corporation from a “c” rating to a “b-” rating in a report on Monday, August 7th. BidaskClub upgraded Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a report on Tuesday, August 8th. Zacks Investment Research upgraded Haemonetics Corporation from a “hold” rating to a “buy” rating and set a $47.00 target price on the stock in a report on Wednesday, August 9th. Barrington Research upgraded Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 target price on the stock in a report on Tuesday, August 8th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $43.00 target price (up from $38.00) on shares of Haemonetics Corporation in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $45.83.

Haemonetics Corporation Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Earnings History for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.